相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
Y. Mei et al.
LEUKEMIA (2018)
The emerging role of immune checkpoint based approaches in AML and MDS
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
Chronic innate immune signaling results in ubiquitination of splicing machinery
Ashley E. Culver-Cochran et al.
CELL CYCLE (2018)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Bjorklund et al.
CLINICAL CANCER RESEARCH (2018)
An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells
Nicole A. P. Lieberman et al.
FRONTIERS IN IMMUNOLOGY (2018)
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Elizabeth A. Griffiths et al.
CLINICAL CANCER RESEARCH (2018)
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M. H. Qazilbash et al.
LEUKEMIA (2017)
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
Jing Fang et al.
NATURE IMMUNOLOGY (2017)
The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression
Allison J. Li et al.
EXPERIMENTAL HEMATOLOGY (2017)
Tet2 restrains inflammatory gene expression in macrophages
Alyssa H. Cull et al.
EXPERIMENTAL HEMATOLOGY (2017)
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
Thomas Cluzeau et al.
HAEMATOLOGICA (2017)
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Julia A. Wagner et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment -Based Drug Design
Katherine L. Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
Uwe Platzbecker et al.
LANCET ONCOLOGY (2017)
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
E. A. Eksioglu et al.
LEUKEMIA (2017)
Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study
Aline S. B. Perazzio et al.
LEUKEMIA RESEARCH (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Alyssa Carey et al.
CELL REPORTS (2017)
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
Thomas Cluzeau et al.
HAEMATOLOGICA (2017)
Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications
Anushruti Sarvaria et al.
FRONTIERS IN IMMUNOLOGY (2017)
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Harry Dolstra et al.
CLINICAL CANCER RESEARCH (2017)
Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms
D. C. Choi et al.
ANNALS OF HEMATOLOGY (2017)
Natural killer cells differentiated in vitro from cord blood CD34+ cells are more advantageous for use as an immunotherapy than peripheral blood and cord blood natural killer cells
Anna Domogala et al.
CYTOTHERAPY (2017)
Stem and progenitor cell alterations in myelodysplastic syndromes
Aditi Shastri et al.
BLOOD (2017)
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome
Astrid Olsnes Kittang et al.
ONCOIMMUNOLOGY (2016)
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Ashley A. Basiorka et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Lohith Bachegowda et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Mintallah Haider et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors
Maximilian Stahl et al.
IMMUNOTHERAPY (2016)
Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs
S. Chen et al.
LEUKEMIA (2016)
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Rebekka K. Schneider et al.
NATURE MEDICINE (2016)
Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts
Anna Mies et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Unraveling the Pathogenesis of MDS: The NLRP3 inflammasome and Pyroptosis Drive the MDS Phenotype
David A. Sallman et al.
FRONTIERS IN ONCOLOGY (2016)
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
Jason Brayer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Carolina Schinke et al.
BLOOD (2015)
Deconstructing innate immune signaling in myelodysplastic syndromes
Melinda E. Varney et al.
EXPERIMENTAL HEMATOLOGY (2015)
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I. Ganan-Gomez et al.
LEUKEMIA (2015)
A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CLINICAL CANCER RESEARCH (2015)
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
Guillermo Garcia-Manero et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Disease Progression in Myelodysplastic Syndromes: Do Mesenchymal Cells Pave the Way?
Marc H. G. P. Raaijmakers
CELL STEM CELL (2014)
Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit
Hind Medyouf et al.
CELL STEM CELL (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody
M. Reilly et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production
Maria Velegraki et al.
HAEMATOLOGICA (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
L. Sokol et al.
LEUKEMIA (2013)
Toll-like receptor alterations in myelodysplastic syndrome
Y. Wei et al.
LEUKEMIA (2013)
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
Frederic Baron et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab
Ankur R. Parikh et al.
SEMINARS IN HEMATOLOGY (2012)
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
Katayoun Rezvani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1
Miroslaw J. Szczepanski et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
Asaka Kondo et al.
BLOOD (2010)
Interleukin-6 and Interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes
Martin R. Schipperus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
Bart L. Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
Bart L. Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Marc H. G. P. Raaijmakers et al.
NATURE (2010)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
Shahram Y. Kordasti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
Apostolia Maria Tsimberidou et al.
CANCER (2008)
Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum
E. Gyan et al.
LEUKEMIA (2008)
Inhibition of p38 alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment
Tony Navas et al.
LEUKEMIA & LYMPHOMA (2008)
The role of the immune system in myelodysplasia: Implications for therapy
Elaine M. Sloand et al.
SEMINARS IN HEMATOLOGY (2008)
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
Katayoun Rezvani et al.
BLOOD (2008)
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti et al.
BLOOD (2007)
Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction:: Disruption of immunological synapse and conjugate formation
Michael Haidinger et al.
TRANSPLANTATION (2007)
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
Z. Y. Lim et al.
LEUKEMIA (2007)
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Pearlie K. Epling-Burnette et al.
BLOOD (2007)
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes
Christos I. Maratheftis et al.
CLINICAL CANCER RESEARCH (2007)
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors
Tony A. Navas et al.
BLOOD (2006)
High mobility group box 1 protein interacts with multiple Toll-like receptors
JS Park et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2006)
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis
G Stifter et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome
CA Meyers et al.
CANCER (2005)
Flow cytometric analysis of the expression of Fas/Fasl in bone marrow CD34+ cells in myelodysplastic syndromes:: Relation to disease progression
E Ribeiro et al.
LEUKEMIA & LYMPHOMA (2004)
Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology
A Pellagatti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes
M Sawanobori et al.
LEUKEMIA RESEARCH (2003)
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
HJ Deeg et al.
LEUKEMIA (2002)
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis
YE Claessens et al.
BLOOD (2002)
分享论文
